Analgesic Advisory Board
Todd Bertoch, MD
Chair, CenExel Analgesic Advisory Board
Chief Medical Officer, CenExel JBR
Dr. Todd Bertoch is board-certified in Anesthesiology by the American Board of Anesthesiology. He received a Bachelor of Science Degree in Biochemistry from California State University at Fullerton and a Doctor of Medicine degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland. After an internship in Internal Medicine, he completed his Anesthesiology residency at Wilford Hall Medical Center in San Antonio, Texas, where he was Chief Resident and received the Arthur B. Tarrow Outstanding Resident Award. He is a member of the esteemed Alpha Omega Alpha Honor Medical Society.
Dr. Bertoch served as an anesthesiologist in the United States Air Force until 2006. Following the terrorist attacks of September 11, 2001, Dr. Bertoch was deployed to Mindanao in the southern Philippines and later to Balad Air Base in Iraq in support of Operation Enduring Freedom. He is a recipient of the Air Force Achievement Medal, the Air Force Commendation Medal, and the Meritorious Service Medal.
After completing his military service, Dr. Bertoch served for 11 years as the managing partner of Prescott Anesthesia in Prescott, Arizona where his practice included a focus on chronic pain management and addiction medicine. He joined CenExel JBR as Chief Scientific Officer in 2017.
Stephen Cooper, DMD PhD
Consultant and Analgesic Research Expert
Dr. Cooper’s doctoral education was at the University of Pennsylvania, School of Dental Medicine. During his D.M.D. training, he became very interested in pharmacology, especially the area of pain control. While in his final year of dental school, he received an NIH/NIDR postdoctoral fellowship to study clinical pharmacology at Georgetown University, School of Medicine. In 1975, he received his Ph.D. from Georgetown and remained on their Medical faculty until 1978. He spent the next 17 years as a Professor and Associate Dean at University of Medicine and Dentistry of New Jersey, University of Pennsylvania and Temple University.
Over this 17- year span, he received grant support from the NIH, private foundations and the pharmaceutical industry totaling over 15 million dollars. His research has focused on clinical pharmacology and pharmacokinetics in a variety of drug groups including analgesics, local anesthetics and intravenous sedation.
From 1995 to 2005, he served as a Senior Vice President of Clinical and Medical Affairs at Wyeth Consumer Healthcare, where he designed and implemented the clinical development plans for Advil Liqui-Gels, Advil Migraine, Advil Cold and Sinus, Advil Allergy and Sinus, Children’s Advil (Suspension, Drops and Chew Tablets), Alavert and Orudis.
Dr. Cooper is most well-known as the developer of the Dental Impaction Pain Model, one of the most widely used pain models in the world. He has published in peer reviewed journals over 100 clinical papers on a wide variety of analgesic drugs. His major areas of expertise are clinical trial design, analgesic drugs and development of consumer products.
Paul Desjardins, DMD, PhD
Consultant, Clinical Pharmacologist and Analgesic Research Expert
Dr. Paul J. Desjardins is a dentist and clinical pharmacologist with 40 years of leadership experience in academic institutions, the pharmaceutical industry and in the drug and device development industries. He the principal scientist and President of Desjardins Associates, LLC. He is an Adjunct Professor at Rutgers School of Dental Medicine and at Tufts University School of Dental Medicine. Dr. Desjardins has consulted with over 45 large and small pharmaceutical companies, medical device companies and law firms since 2011. He is the Emeritus Chairman of the Tufts Dental School Board of Advisors and an active member of the South Orange Performing Arts Center (SOPAC) Board of Governors.
From 2005 – 2011, he served as Sr Vice-President, Global Clinical and Medical Affairs for Pfizer Consumer Healthcare (PCH) in Madison NJ. There, he led a group of 40 physicians, nutritionists, dentists, pharmacists, toxicologists, statisticians and clinical scientists who developed new over-the-counter (OTC) analgesics, multivitamins, cough and cold, and personal care products. His teams designed clinical research programs and provided medical support for marketed PCH products worldwide for products like Advil, Robitussin, Dimetapp, Caltrate, Centrum Multivitamins and Thermacare Heat Wraps.
From 1998 to 2005, Dr. Desjardins served Executive Vice President for Analgesic Clinical Research at SCIREX Corporation, a clinical research organization that specialized in acute and chronic pain studies. He and his team operated 7 clinical research centers. He led the development and refinement of the post-bunionectomy, dental impaction and acute low back pain models that have been utilized in over 100 clinical trials in 45 different drug and device development programs. He is considered one of the world’s experts in acute pain model development in humans and has published over 200 publications, posters and book chapters on human pain models and the efficacy of new analgesic drugs.
From 1981 to 1998, Dr. Desjardins enjoyed a successful academic career at the UMDNJ – New Jersey Dental School (Now Rutgers School of Dental Medicine) where he served as Professor of Oral Surgery and Oral Biology and Associate Dean for Academic Affairs. He led the curriculum revision which refocused much of the dental curriculum to be based on clinical competencies, small group teaching, problem based learning and Community Oriented Dental Education. He continues to teach in graduate courses and continuing dental education at Tufts and Rutgers.
Dr. Desjardins received his BS with honors in Pharmacology and Toxicology from the University of Rhode Island. He received his DMD from Tufts University School of Dental Medicine and his Ph.D. in Pharmacology from Georgetown University. He completed a 2 year hospital-based General Practice Residency in Rochester, NY.